APRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aprea Therapeutics Inc (APRE) is not a strong buy for a beginner, long-term investor at this time. The company is in a challenging financial position with declining revenue and net income, and while there are some positive developments in its clinical trials, the lack of significant recent news, weak financial performance, and absence of strong trading signals suggest a cautious approach. Holding off on investing until more positive financial or clinical data emerges would be prudent.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is in the neutral zone at 72.557, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its resistance level of 0.86, with key support at 0.73.
Insiders are buying, with a 147.37% increase in buying activity over the last month. Analysts remain optimistic about the clinical potential of APR-1051, with ongoing trials showing promising early results.
Revenue dropped significantly by 99.48% YoY in Q3 2025, and net income and EPS also declined. Analysts have consistently lowered price targets due to dilution and financial challenges. No recent news or significant hedge fund activity to support a bullish sentiment.
In Q3 2025, revenue dropped by 99.48% YoY to $1,848. Net income declined by 21.44% YoY to -$2,972,410, and EPS fell by 26.56% YoY to -$0.47. Gross margin remained stable at 100%. Overall, the financial performance is weak, with significant declines in key metrics.
Analysts have lowered price targets over the last few months, with Wedbush reducing its target to $7 and H.C. Wainwright lowering its target to $4. Despite the cuts, both firms maintain positive ratings (Outperform and Buy) due to promising clinical trial data for APR-1051.
